Zyprexa patent litigation

Joint stipulation staying Lilly's Zyprexa patent infringement action against Teva "has no significance or bearing" on Ivax' litigation over the olanzapine patent, Ivax says. Under the stipulation, Teva will not actively participate in the litigation but will be bound by the court's decision on the Zyprexa patent. Ivax says Teva was the third company sued by Lilly and has not actively participated in the case since it was consolidated in November with Lilly's earlier lawsuits against Ivax and Dr. Reddy's. Ivax says it holds first-to-file status on five dosage strengths, with Reddy's believed to be first to file on one dosage strength. Trial is scheduled for January (1"The Pink Sheet" April 7, 2003, p. 33)...